Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 6, 2007, Pages 676-683

  Michel, Olivier ^a   Dentener, Mieke ^b   Cataldo, Didier ^c   Cantinieaux, Brigitte ^a   Vertongen, Françoise ^a   Delvaux, Catherine ^a   Murdoch, Robert D ^d  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Acute phase proteins; Asthma; Corticosteroid; Endotoxin; Gelatinolytic activity; Induced sputum; Inflammation; Lipopolysaccharide; Neutrophils; PDE4 inhibitor

Indexed keywords

C REACTIVE PROTEIN; CILOMILAST; CORTICOSTEROID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE IV INHIBITOR; PREDNISOLONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; BODY TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; NEUTROPHIL; NEUTROPHILIA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CARBOXYLIC ACIDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; E-SELECTIN; FEMALE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEUTROPHILS; NITRILES; PHOSPHODIESTERASE INHIBITORS; PREDNISOLONE; SPUTUM; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548837748     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.08.002     Document Type: Article

References (40)

1. Rylander R, editor. Endotoxins in the environment: a criteria document. Int J Occup Environ Health 1997; 3 (Suppl. 1): S1-48.
2. Hasday J.D., Bascom R., Costa J.J., Fitzgerald T., and Dubin W. Bacterial endotoxin is an active component of cigarette smoke. Chest 115 (1999) 829-835
3. Park J.-H., Gold D.R., Spiegelma D.L., Burge H.A., and Milton D.K. House dust endotoxin and wheeze in the first year of life. Am J Respir Crit Care Med 163 (2001) 322-328
4. Michel O., Kips J., Duchateau J., Vertongen F., Robert L., Collet H., et al. Severity of asthma is related to endotoxin in house dust. Am J Respir Crit Care Med 154 (1996) 1641-1646
5. Thorne P.S., Kulhankova K., Yin M., Cohn R., Arbes S.J., and Zeldin D.C. Endotoxin exposure is a risk factor for asthma. Am J Respir Crit Care Med 172 (2005) 1371-1377
6. Michel O., Nagy A.M., Schroeven M., Duchateau J., Neve J., Fondu P., et al. Dose-response relationship to inhaled endotoxin in normal subjects. Am J Respir Crit Care Med 156 (1997) 1157-1164
7. Thorn J., and Rylander R. Inflammatory response after inhalation of bacterial endotoxin assessed by the induced sputum technique. Thorax 53 (1998) 1047-1052
8. Nightingale J.A., Rogers D.F., Hart L.A., Kharitonov S.A., Chung K.F., and Barnes P.J. Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects. Thorax 53 (1998) 563-571
9. Michel O., Dentener M., Corazza F., Buurman W., and Rylander R. Normal subjects express differences in clinical responses to inhaled lipopolysaccharide wich are related with inflammation and with atopy. J Allergy Clin Immunol 107 (2001) 797-804
10. Vecchiarelli A., Siracusa A., Cenci E., Puliti M., and Abbritti G. Effect of corticosteroid treatment on interleukin-1 and tumor necrosis factor secretion by monocytes from subjects with asthma. Clin Exp Allergy 22 (1992) 365-370
11. Martinet N., Vaillant P., Charles T., Lambert J., and Martinet Y. Dexamethasone modulation of tumor necrosis factor-α (cachectin) release by activated normal human alveolar macrophages. Eur Respir J 5 (1992) 67-72
12. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157 (1998) 351-370
13. Barnette M.S., Christensen S.B., Essayan D.M., Grous M., Prabhakar U., Rush J.A., et al. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 284 (1998) 420-426
14. Underwood D.C., Osborn R.R., Bochnowicz S., Rieman D.J., Romanic A.M., Hay D.W.P., et al. Ariflo (SB 207499) inhibits airway neutrophilia, inflammatory cytokine production and matrix metalloproteinase-9 activity in the guinea pig (abstract). Am J Respir Crit Care Med 161 (2000) A492
15. Pavord I.D., Pizzichini M.M.M., Pizzichini E., and Hargraeve F.E. The use of induced sputum to investigate airway inflammation. Thorax 52 (1997) 498-501
16. Cataldo D., Munaut C., Noel A., Frankenne F., Bartsch P., Foidart J., et al. MMP-2 and MMP-9 linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 123 (2000) 259-267
17. Bishop C.R., Athens J.W., Boggs D.R., Warner H.R., Cartwright G.E., and Wintrobe M.M. Leukokinetic studies: a non-steady-state kinetic evaluation of the mechanism of cortisone-induced granulocytosis. J Clin Invest 47 2 (1968) 249-260
18. Max J., Bochner B.S., Schleimer R.P., and Beck L.A. The effect of systemic glucocorticoids on cutaneous IL-1β production, endothelial E-selectin expression and PMN infiltration after bacterial endotoxin injection in human subjects (abstract). J Allergy Clin Immunol 99 (1997) S337
19. Culpitt S.V., Maziak W., Loukidis S., Nightingale J.A., Matthews J.L., and Barnes P.J. Effect of high dose inhaled steroids on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 (1999) 1635-1639
20. Keatings V.M., Jatakanon A., Worsdell Y.M., and Barnes P.J. Effetcs of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 155 (1997) 542-548
21. Hasett C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med 160 (1999) S5-S11
22. Sadikot R.T., Jansen E.D., Blackwell T.R., Zoia O., Yull F., Christman J.W., et al. High-dose dexamethasone accentuates nuclear factor-κB activation in endotoxin-treated mice. Am J Respir Crit Care Med 164 (2001) 873-878
23. Mercer P.F., Shute J.K., Bhowmik A., Donaldson G.C., Wedzicha J.A., and Warner J.A. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res 6 (2005) 151-159
24. Lefort J., Motreff L., and Vargaftig B. Airway administration of Escherichia coli endotoxin to mice induces glucocoticosteroid-resistant bronchoconstriction and vasopermeation. Am J Respir Cell Mol Biol 24 (2001) 34-351
25. Woolley S.T., Weyman-Jones C., and Young A. A comparison of the effect of PDE4 inhibitor on neutrophilia and cytokine expression in a murine model of LPS-induced lung inflammation (abstract). Eur Respir J 16 Suppl. 31 (2000) 539s
26. O'Leary E.C., Marder P., and Zuckerman S.H. Glucocorticoid effects in an endotoxin-induced rat pulmonary inflammation model: differential effects on neutrophil influx, integrin expression, and inflammatory mediators. Am J Respir Cell Mol Biol 15 (1996) 97-106
27. Scheilmer R.P., Spahn J.D., Covar R., and Szefler S. Glucocorticoids. In: Adkinson N.F., Yunginger J.W., Busse W.W., et al. (Eds). Middleton's allergy principles and practice (2003), Mosby, Philadelphia 870-913
28. Barber A.E., Coyle S.M., Marano M.A., Fischer E., Calvano S.E., Fong Y., et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 150 (1993) 1999-2006
29. Alvarez J., Surs W., Leung D.Y.M., Ikle D., Gelfand E.W., and Szefler S. Steroid-resitant asthma: immunologic and pharmacologic features. J Allergy Clin Immunol 89 (1992) 714-721
30. Pipkorn U., Proud D., Lichtenstein L.M., Schleimer R.P., Peters S.P., Adkinson Jr. N.F., et al. Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J Clin Invest 80 (1987) 957-961
31. Webb J.R. Dose response of patients to oral corticosteroid treatment during exacerbations of asthma. Br Med J Clin Res Ed 292 (1986) 1045-1049
32. Rylander R., Bake B., Fischer J.J., and Helander I.M. Pulmonary function and symptoms after inhalation of endotoxin. Am Rev Respir Dis 140 (1989) 981-986
33. Michel O., LeVan T.D., Stern D., Dentener M., Thorn J., Gnat D., et al. Systemic responsiveness to lipopolyssacharide and polymorphisms in the Toll-like receptor 4 gene in humans. J Allergy Clin Immunol 112 (2003) 928-934
34. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
35. Michel O., Olbrecht J., Moulard D., and Sergysels R. Effect of anti-asthmatic drugs on the response to inhaled endotoxin. Ann Allergy Asthma Immunol 85 (2000) 305-310
36. Compton C.H., Gubb J., Nieman R., Edelson J., Amit O., Bakst A., et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358 (2001) 256-257
37. Gamble E., Grootendorst D.C., Brightling E., Troy S., Qiu Y., Zhu J., et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 168 (2003) 976-982
38. Prabhakar U., Lipshutz D., Bartus J.O., Slivjak M.J., Smith III E.F., Lee J.C., et al. Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Pharmacol 16 (1994) 805-816
39. Griswold D.E., Webb E.F., Badger A.M., Gorycki P.D., Levandoski P.A., Barnette M.A., et al. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor æ and interleukin-4 production in vivo. J Pharmacol Exp Ther 287 (1998) 705-711
40. Spond J., Chapman R., Fine J., Jones H., Kreutner W., Kung T.T., et al. Comparison of PDE4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther 14 (2001) 157-164